102 related articles for article (PubMed ID: 30663337)
1. Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer.
Hochheiser L; Hornberger J; Turner M; Lyman GH
J Comp Eff Res; 2019 Apr; 8(5):289-304. PubMed ID: 30663337
[TBL] [Abstract][Full Text] [Related]
2. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
[TBL] [Abstract][Full Text] [Related]
5. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
6. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
[TBL] [Abstract][Full Text] [Related]
7. Prospective cost-effectiveness analysis of genomic profiling in breast cancer.
Retèl VP; Joore MA; Drukker CA; Bueno-de-Mesquita JM; Knauer M; van Tinteren H; Linn SC; van Harten WH
Eur J Cancer; 2013 Dec; 49(18):3773-9. PubMed ID: 23992641
[TBL] [Abstract][Full Text] [Related]
8. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
Hornberger J; Cosler LE; Lyman GH
Am J Manag Care; 2005 May; 11(5):313-24. PubMed ID: 15898220
[TBL] [Abstract][Full Text] [Related]
11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
12. Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer.
Henderson J; Adams P; Barber K
Clin Breast Cancer; 2019 Jun; 19(3):e475-e480. PubMed ID: 30852142
[TBL] [Abstract][Full Text] [Related]
13. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
14. Changes of expression of estrogen and progestrone receptors, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy in the treatment of breast cancer.
Li ML; Dong Y; Luan SL; Zhao ZH; Ning FL
J Biol Regul Homeost Agents; 2016; 30(4):1059-1065. PubMed ID: 28078854
[TBL] [Abstract][Full Text] [Related]
15. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
16. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
17. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
18. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
[TBL] [Abstract][Full Text] [Related]
19. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A
Curr Med Res Opin; 2015 Jun; 31(6):1129-37. PubMed ID: 25851308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
